Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination-Reference-Cited by-同舟云学术

Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination

Published:2021-05-09 Issue:1 Volume:164 Page:90-105
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Baksmeier Christine¹,Blundell Pat²,Steckel Julia¹,Schultz Verena³,Gu Quan³,Da Silva Filipe Ana³,Kohl Alain³,Linnington Chris³,Lu Dongli⁴,Dell Anne⁴,Haslam Stuart⁴,Wang Jiabin⁵,Czajkowsky Dan⁶,Goebels Norbert¹,Pleass Richard J.²^ORCID

Affiliation:

1. Department of Neurology Medical Faculty Heinrich‐Heine‐University Duesseldorf Duesseldorf Germany

2. Department of Tropical Disease Biology Liverpool School of Tropical Medicine Liverpool UK

3. Institute of Infection, Immunity and Inflammation College of Medical Veterinary and Life Sciences University of Glasgow Glasgow UK

4. Department of Life Sciences Imperial College London London UK

5. Shanghai Center for Systems Biomedicine Key Laboratory of Systems Biomedicine (Ministry of Education) Shanghai Jiao Tong University Shanghai China

6. State Key Laboratory for Oncogenes and Related Genes and Bio‐ID Center School of Biomedical Engineering Shanghai Jiao Tong University Shanghai China

Funder

Medical Research Council

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13341

Reference81 articles.

1. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

2. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy

3. IVIG in autoimmune disease — Potential next generation biologics

4. Guillain–Barré syndrome: a century of progress

5. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Charting a course for global progress in PIDs by 2030 — proceedings from the IPOPI global multi-stakeholders’ summit (September 2023);Frontiers in Immunology;2024-06-27

2. Sialylation as an Important Regulator of Antibody Function;Frontiers in Immunology;2022-04-07

3. The therapeutic potential of sialylated Fc domains of human IgG;mAbs;2021-01-01